{"id":"hydroquinidine","rwe":[{"pmid":"41789825","year":"2026","title":"Organocatalytic Asymmetric α-C-H Allylation of N-Arylidene-Protected Alkyl Amines.","finding":"","journal":"Organic letters","studyType":"Clinical Study"},{"pmid":"41778209","year":"2026","title":"Resolution of severe dilated cardiomyopathy with significant arrhythmia burden using hydroquinidine, in addition to guideline-directed medical therapy, in a patient with a pathogenic SCN5A variant: a case report.","finding":"","journal":"European heart journal. Case reports","studyType":"Clinical Study"},{"pmid":"41114121","year":"2025","title":"Gut microbiota and metabolite changes in metastatic colorectal cancer via 16S rRNA and metabolomics.","finding":"","journal":"World journal of gastrointestinal oncology","studyType":"Clinical Study"},{"pmid":"40137421","year":"2025","title":"The Uncommon Phenomenon of Short QT Syndrome: A Scoping Review of the Literature.","finding":"","journal":"Journal of personalized medicine","studyType":"Clinical Study"},{"pmid":"39675648","year":"2025","title":"Noninvasive assessment of hydroquinidine effect in Brugada syndrome (QUIET BrS).","finding":"","journal":"Heart rhythm","studyType":"Clinical Study"}],"tags":[{"label":"hydroquinidine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium voltage-gated channel subfamily H member 2","category":"target"},{"label":"KCNH2","category":"gene"},{"label":"SCN5A","category":"gene"},{"label":"SCN1B","category":"gene"},{"label":"C01BA13","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Parasympatholytics","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"discontinued","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"hydroconquinine","offLabel":[],"synonyms":["dihydroquinidine","hydroconquinine","hydroquinidine","hydroquinidine hydrochloride","hydroquinidine HCl"],"timeline":[],"aiSummary":"Hydroquinidine is a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It is classified as a hydroquinidine and its mechanism of action involves blocking potassium channels, which can help regulate heart rhythm. However, its commercial status and approved indications are unknown. As a result, its availability and use are limited. Further research is needed to determine its potential as a therapeutic agent.","approvals":[],"brandName":"Hydroconquinine","ecosystem":[],"mechanism":{"target":"Sodium channel subunit beta-1, Sodium channel subunit beta-2, Sodium channel subunit beta-3","targets":[{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha"},{"gene":"SCN1B","source":"DrugCentral","target":"Sodium channel subunit beta-1","protein":"Sodium channel subunit beta-1"},{"gene":"SCN2B","source":"DrugCentral","target":"Sodium channel subunit beta-2","protein":"Sodium channel subunit beta-2"},{"gene":"SCN3B","source":"DrugCentral","target":"Sodium channel subunit beta-3","protein":"Sodium channel subunit beta-3"},{"gene":"SCN4B","source":"DrugCentral","target":"Sodium channel subunit beta-4","protein":"Sodium channel subunit beta-4"}],"modality":"Small Molecule","drugClass":"hydroquinidine","explanation":"Think of your heart like a pump that beats at a certain rate. Potassium channels help control how fast the heart beats. Hydroquinidine blocks these channels, which can help slow down an irregular heartbeat and make it more regular.","oneSentence":"Hydroquinidine works by blocking potassium channels in the heart to help regulate heart rhythm.","technicalDetail":"Hydroquinidine acts as a selective blocker of the potassium voltage-gated channel subfamily H member 2 (Kv11.1), which is a key regulator of the cardiac action potential duration and rate of repolarization."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/889","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=HYDROQUINIDINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYDROQUINIDINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:53:59.932794","biosimilars":[],"competitors":[{"drugName":"quinidine","drugSlug":"quinidine","fdaApproval":"1950-07-12","genericCount":35,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"procainamide","drugSlug":"procainamide","fdaApproval":"1950-06-02","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"disopyramide","drugSlug":"disopyramide","fdaApproval":"1977-09-01","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"hydroquinidine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"quinidine","brandName":"quinidine","genericName":"quinidine","approvalYear":"1950","relationship":"same-class"},{"drugId":"procainamide","brandName":"procainamide","genericName":"procainamide","approvalYear":"1950","relationship":"same-class"},{"drugId":"disopyramide","brandName":"disopyramide","genericName":"disopyramide","approvalYear":"1977","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00789165","phase":"PHASE2,PHASE3","title":"Empiric Quinidine for Asymptomatic Brugada Syndrome","status":"WITHDRAWN","sponsor":"International Registry of Asymptomatic Brugada Syndrome","startDate":"2009-12","conditions":["Arrhythmia"],"enrollment":0,"completionDate":"2020-12-31"},{"nctId":"NCT00927732","phase":"PHASE3","title":"Hydroquinidine Versus Placebo in Patients With Brugada Syndrome","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2009-02","conditions":["Brugada Syndrome"],"enrollment":64,"completionDate":"2014-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005252","UNII":"8P68XPY4HG","CHEBI":"CHEBI:5792","RXNORM":"236160","UMLSCUI":"C0063103","ChEMBL_ID":"CHEMBL1906890","KEGG_DRUG":"D08048","DRUGBANK_ID":"DB15300","PUBCHEM_CID":"121515","SNOMEDCT_US":"765387007","SECONDARY_CAS_RN":"1476-98-8","MESH_SUPPLEMENTAL_RECORD_UI":"C014486"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.7 hours","clearance":"4.2 mL/min/kg","fractionUnbound":"0.22%","volumeOfDistribution":"2.8 L/kg"},"publicationCount":119,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01BA13","allCodes":["C01BA13"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 20","pmid":"41789825","title":"Organocatalytic Asymmetric α-C-H Allylation of N-Arylidene-Protected Alkyl Amines.","journal":"Organic letters"},{"date":"2026 Mar","pmid":"41778209","title":"Resolution of severe dilated cardiomyopathy with significant arrhythmia burden using hydroquinidine, in addition to guideline-directed medical therapy, in a patient with a pathogenic SCN5A variant: a case report.","journal":"European heart journal. Case reports"},{"date":"2025 Oct 15","pmid":"41114121","title":"Gut microbiota and metabolite changes in metastatic colorectal cancer via 16S rRNA and metabolomics.","journal":"World journal of gastrointestinal oncology"},{"date":"2025 Mar 8","pmid":"40137421","title":"The Uncommon Phenomenon of Short QT Syndrome: A Scoping Review of the Literature.","journal":"Journal of personalized medicine"},{"date":"2025 Nov","pmid":"39675648","title":"Noninvasive assessment of hydroquinidine effect in Brugada syndrome (QUIET BrS).","journal":"Heart rhythm"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}